"Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...

This downside came after Vaxcyte reported mixed results from a phase II study on its investigational pneumococcal conjugate vaccine (PCV) in healthy infants. Adding to this headwind, the broader ...

Pneumococcal 20-valent conjugate vaccine (diphtheria CRM197 protein ... in a control group receiving 13-valent pneumococcal conjugate vaccine (Prevnar 13) followed 1 month later with 23-valent ...

The company is also evaluating VAX-31, a 31-valent, carrier-sparing PCV ... IPD vaccine trial success" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...

Given the uncertain regulatory environment, I am downgrading Vaxcyte's stock to "Hold" until there's more clarity on the FDA's stance on PCV vaccines. Phase 2 dose-finding study evaluating the ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

In the past month, PCVX's shares have nosedived 56%. This downside came after Vaxcyte reported mixed results from a phase II study on its investigational pneumococcal conjugate vaccine (PCV) in ...